Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: J Am Coll Cardiol. 2018 May 1;71(17):1857–1865. doi: 10.1016/j.jacc.2018.02.055

Figure 1. Association of metabolic syndrome with cardiovascular disease (Odds ratios and 95% confidence intervals) in 2744 MESA participants with obesity.

Figure 1

Estimates for Baseline, Ever Across Follow-Up, and Change Across Follow-Up are significantly different at the p<0.05 level. For duration of MetS p-value for trend was p<0.001. MetS=Metabolic syndrome. All models adjusted for age, sex, race/ethnicity, education, income, smoking status, LDL cholesterol, and statin use. Sample sizes: At baseline n=1033 for No MetS; n=1159 for MetS. Ever across follow-up n=685 for No MetS and n=2059 for Ever MetS. Change across follow-up n=685 for No MetS; n=1434 for Intermittent MetS; n=625 for Continuous MetS. Duration across follow-up n=685 for No MetS; n=448 for MetS 1 visit; n=371 for MetS 2 Visits; n=1240 for MetS 3+ Visits.